NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Category: FDA

9/13/2017

Worrisome ‘right to try’ legislation may soon become law. Here’s the story that some news outlets missed

8/29/2017

FDA announces action against two stem cell clinics: Is that a ‘crackdown’?    

2 7/11/2017

Fact-checking pharma: 5 cancer drug myths, busted

1 1/26/2017

Approval of ‘breakthrough’ hepatitis C drugs isn’t even half the story; now come the harms

1/9/2017

Whitewashing a black box warning: The Chantix story that didn’t get told

11 12/6/2016

With media watchdogs on the sidelines, pharma-funded advocacy groups pushed Cures Act to the finish line  

1 11/29/2016

Off-label drug marketing: Who will decide what’s “truthful” when the evidence can’t be trusted?   

10/31/2016

Early report card on quality of FDA news releases: C at best

10/25/2016

Black box warnings for ‘lifesaving’ hepatitis C drugs highlight systematic misinformation

3 9/28/2016

What some stories missed about the muscular dystrophy drug approval: Pharma’s close ties to vocal patient advocacy groups

Blog

Opinions on other issues in news, journals, PR, advertising, marketing

@HealthNewsRevu

HealthNewsRevuHealthNewsReview.org@HealthNewsRevu·

Our 3,222 reviews of health care journalism & PR will be gone soon. The rest of the website will remain. Read details. https://www.healthnewsreview.org/2021/01/our-3222-systematic-reviews-of-journalism-pr-will-be-gone-soon/

Reply on Twitter 1351160348615782403Retweet on Twitter 13511603486157824031Like on Twitter 13511603486157824032Twitter 1351160348615782403
HealthNewsRevuHealthNewsReview.org@HealthNewsRevu·

Year-ender: links to all 44 articles I published in 2020 - a year of too-frequent distortion, deceit and misinformation, worst I’ve seen in my 47-year career. https://www.healthnewsreview.org/2020/12/reflections-on-2020-you-cant-mask-this-reality/

Reply on Twitter 1343561730203525122Retweet on Twitter 13435617302035251229Like on Twitter 13435617302035251227Twitter 1343561730203525122
Retweet on TwitterHealthNewsReview.org Retweeted
IJNetIJNet@IJNet·

“The distinction between what we do know and what we do not yet understand should be explained more often and more clearly in our coverage,” said @garyschwitzer. Journalists need to get past press releases from drug companies, but also debunk conspiracies. https://buff.ly/2LX9MVo

Reply on Twitter 1342696898508029952Retweet on Twitter 13426968985080299525Like on Twitter 13426968985080299529Twitter 1342696898508029952
View More

Categories

View More

Tags